MedTrace Logo

Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain

NCT01466764 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-08-09

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that perioperative administration of anakinra will reduce incisional pain by lowering the concentration of inflammatory mediators in surgical wounds. This knowledge is important because it suggests a new, previously unexplored pharmacological target for the control of postoperative incisional pain.

Conditions

Interventions

DRUG

Anakinra

An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.

OTHER

Normal Saline

An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.

Sponsors & Collaborators

Principal Investigators

  • Robert L Lobato, MD · Stanford U

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-05-31
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01466764 on ClinicalTrials.gov